{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:56Z","timestamp":1791471776890,"version":"4.3.4"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1001\/jamadermatol.2019.2855","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T11:31:27Z","timestamp":1570015887000},"page":"1371","source":"Crossref","is-referenced-by-count":234,"title":["Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis"],"prefix":"10.1001","volume":"155","author":[{"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[{"name":"SKiN Centre for Dermatology, Peterborough, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth B.","family":"Forman","sequence":"additional","affiliation":[{"name":"Forward Clinical Trials, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Innovaderm Research, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S.","family":"Beebe","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Innovative Health Statistics, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Banfield","sequence":"additional","affiliation":[{"name":"Early Clinical Development Unit, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zhu","sequence":"additional","affiliation":[{"name":"Early Clinical Development Unit, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Papacharalambous","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi190050r1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi190050r2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/pde.2005.22.issue-3","article-title":"The burden of atopic dermatitis: impact on the patient, family, and society.","volume":"22","author":"Carroll","year":"2005","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"doi190050r3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies.","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"doi190050r4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis, section 2: management and treatment of atopic dermatitis with topical therapies.","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi190050r5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi190050r8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/imr.2009.228.issue-1","article-title":"Janus kinases in immune cell signaling.","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"issue":"3","key":"doi190050r9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"doi190050r10","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis.","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"issue":"5","key":"doi190050r11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.2016.175.issue-5","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi190050r12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjd.16014","article-title":"Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.","volume":"178","author":"Nakagawa","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi190050r13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"doi190050r15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"24","key":"doi190050r18","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"doi190050r19","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases.","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"doi190050r20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"doi190050r6","year":"2017"},{"key":"doi190050r7","year":"2018"},{"key":"doi190050r14","author":"Guttman-Yassky"},{"key":"doi190050r16","doi-asserted-by":"crossref","DOI":"10.1201\/9781420060669","volume-title":"Computational Pharmacokinetics","author":"Kallen","year":"2007"},{"key":"doi190050r17","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2018"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2751870\/jamadermatology_gooderham_2019_oi_190050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T11:02:21Z","timestamp":1578481341000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2751870"}},"subtitle":["A Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}